<p>Disc Medicine, Inc.（納斯達克代碼：IRON - 獲取免費報告）內部人士 William Jacob Savage 於 12 月 15 日（星期一）出售了該公司 13,093 股股票。股票的平均售價為 91.22 美元，總交易額為 1,194,343.46 美元。出售完成後，該內部人士在公司持有 75,702 股，價值 6,905,536.44 美元。這代表其持股比例減少了 14.75%。該交易已在美國證券交易委員會的備案中披露，具體信息可通過此鏈接查看。</p>
<p>獲取 <strong>Disc Medicine</strong> 警報：</p>
<h2>Disc Medicine 股票下跌 0.6%</h2>
<p>週二交易時段，納斯達克 IRON 的股票下跌 0.53 美元，報 91.47 美元。該股票交易量為 639,414 股，而其平均交易量為 536,679 股。Disc Medicine, Inc.的 12 個月最低價為 30.82 美元，最高價為 99.50 美元。該公司的 50 日移動平均價格為 86.99 美元，200 日移動平均價格為 68.22 美元。公司的速動比率為 23.45，流動比率為 23.45，債務與股本比率為 0.05。公司的市值為 34.5 億美元，市盈率為-17.10，貝塔係數為 0.87。</p>
<p>Disc Medicine（納斯達克代碼：IRON - 獲取免費報告）最近一次公佈財報是在 11 月 6 日（星期四）。公司報告季度每股收益為-1.77 美元，低於市場共識預期的-1.48 美元，差額為-0.29 美元。賣方分析師平均預計 Disc Medicine, Inc.在當前年度的每股收益為-4.07 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家券商最近對 IRON 進行了評估。摩根士丹利在 10 月 30 日的研究報告中將 Disc Medicine 的目標價從 90.00 美元上調至 115.00 美元，並給予該股票 “增持” 評級。Stifel Nicolaus 在 11 月 3 日的報告中開始覆蓋 Disc Medicine，給予 “買入” 評級和 125.00 美元的目標價。National Bankshares 在 10 月 17 日的報告中對 Disc Medicine 的股票設定了 153.00 美元的目標價。Cantor Fitzgerald 在 10 月 17 日的研究報告中將 Disc Medicine 的目標價從 132.00 美元上調至 153.00 美元，並給予 “增持” 評級。最後，Wedbush 在 10 月 17 日的研究報告中將 Disc Medicine 的目標價從 90.00 美元上調至 110.00 美元，並給予 “跑贏大盤” 評級。一位投資分析師對該股票給予了強烈買入評級，十位分析師給予買入評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 119.00 美元。</p>
<p><strong>獲取我們最新的 IRON 股票分析</strong></p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者最近調整了對該公司的持股。Aster Capital Management DIFC Ltd 在第三季度收購了 Disc Medicine 的新股份，價值約 38,000 美元。CWM LLC 在第二季度將其在 Disc Medicine 的持股增加了 213.5%。CWM LLC 目前持有 1,044 股該公司的股票，價值 55,000 美元，此前在上個季度又購買了 711 股。Avanza Fonder AB 在第二季度收購了 Disc Medicine 的新股份，價值 57,000 美元。Mirae Asset Global Investments Co. Ltd.在第二季度將其在 Disc Medicine 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd.目前持有 1,338 股該公司的股票，價值 71,000 美元，此前在此期間又購買了 181 股。最後，Ameritas Investment Partners Inc.在第二季度將其在 Disc Medicine 的持股增加了 8.9%。Ameritas Investment Partners Inc.目前持有 2,515 股該公司的股票，價值 133,000 美元，此前在上個季度又購買了 206 股。當前 83.70% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Disc Medicine</h2>
<p>（獲取免費報告）</p>
<p>Disc Medicine, Inc.及其子公司是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化針對美國嚴重血液疾病患者的新治療方案。該公司已組建了一系列臨牀和臨牀前產品候選者，旨在改變與紅細胞形成和功能相關的基本生物途徑，主要是血紅素生物合成和鐵穩態。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Disc Medicine</li>
<li>公用事業股票解析 – 如何以及為何投資公用事業</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個明智的買入</li>
<li>投資者如何識別併成功交易缺口下跌股票</li>
<li>RTX 因國防訂單激增而飆升至歷史新高</li>
<li>三大醫療股息股票值得買入和持有</li>
<li>聰明資金正在購買汽車供應商，而不是汽車品牌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Disc Medicine 嗎？</h2>
<p>在考慮 Disc Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Disc Medicine 並不在名單上。</p>
<p>雖然 Disc Medicine 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

IRON

<p>Disc Medicine 的內部人士 William Jacob Savage 出售了 13,093 股，每股售價為 91.22 美元，總計 1,194,343.46 美元。此次出售使他的持股減少了 14.75%，剩餘 75,702 股，價值 6,905,536.44 美元。該交易已向美國證券交易委員會（SEC）披露。Disc Medicine 的股票下跌了 0.6%，報 91.47 美元。分析師對該股票給予了 “適度買入” 的評級，目標價共識為 119.00 美元。機構投資者正在調整他們在公司的持股</p>

<p>Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider William Jacob Savage sold 13,093 shares of the firm's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the completion of the sale, the insider owned 75,702 shares in the company, valued at $6,905,536.44. This represents a 14.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.（納斯達克代碼：IRON - 獲取免費報告）內部人士 William Jacob Savage 於 12 月 15 日（星期一）出售了該公司 13,093 股股票。股票的平均售價為 91.22 美元，總交易額為 1,194,343.46 美元。出售完成後，該內部人士在公司持有 75,702 股，價值 6,905,536.44 美元。這代表其持股比例減少了 14.75%。該交易已在美國證券交易委員會的備案中披露，具體信息可通過此鏈接查看。</p>
</div><p>Get <strong>Disc Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Disc Medicine</strong> 警報：</p>
</div><h2>Disc Medicine Stock Down 0.6%</h2>
<div class="lb-trans"><h2>Disc Medicine 股票下跌 0.6%</h2>
</div><p>Shares of NASDAQ IRON traded down $0.53 during trading hours on Tuesday, hitting $91.47. 639,414 shares of the stock were exchanged, compared to its average volume of 536,679. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $99.50. The firm has a fifty day moving average price of $86.99 and a 200-day moving average price of $68.22. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.45 billion, a PE ratio of -17.10 and a beta of 0.87.</p>
<div class="lb-trans"><p>週二交易時段，納斯達克 IRON 的股票下跌 0.53 美元，報 91.47 美元。該股票交易量為 639,414 股，而其平均交易量為 536,679 股。Disc Medicine, Inc.的 12 個月最低價為 30.82 美元，最高價為 99.50 美元。該公司的 50 日移動平均價格為 86.99 美元，200 日移動平均價格為 68.22 美元。公司的速動比率為 23.45，流動比率為 23.45，債務與股本比率為 0.05。公司的市值為 34.5 億美元，市盈率為-17.10，貝塔係數為 0.87。</p>
</div><p>Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, sell-side analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.</p>
<div class="lb-trans"><p>Disc Medicine（納斯達克代碼：IRON - 獲取免費報告）最近一次公佈財報是在 11 月 6 日（星期四）。公司報告季度每股收益為-1.77 美元，低於市場共識預期的-1.48 美元，差額為-0.29 美元。賣方分析師平均預計 Disc Medicine, Inc.在當前年度的每股收益為-4.07 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several brokerages recently weighed in on IRON. Morgan Stanley boosted their target price on Disc Medicine from $90.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, October 30th. Stifel Nicolaus initiated coverage on Disc Medicine in a report on Monday, November 3rd. They issued a &#34;buy&#34; rating and a $125.00 price target for the company. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a report on Friday, October 17th. Cantor Fitzgerald lifted their target price on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, October 17th. Finally, Wedbush boosted their target price on shares of Disc Medicine from $90.00 to $110.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $119.00.</p>
<div class="lb-trans"><p>幾家券商最近對 IRON 進行了評估。摩根士丹利在 10 月 30 日的研究報告中將 Disc Medicine 的目標價從 90.00 美元上調至 115.00 美元，並給予該股票 “增持” 評級。Stifel Nicolaus 在 11 月 3 日的報告中開始覆蓋 Disc Medicine，給予 “買入” 評級和 125.00 美元的目標價。National Bankshares 在 10 月 17 日的報告中對 Disc Medicine 的股票設定了 153.00 美元的目標價。Cantor Fitzgerald 在 10 月 17 日的研究報告中將 Disc Medicine 的目標價從 132.00 美元上調至 153.00 美元，並給予 “增持” 評級。最後，Wedbush 在 10 月 17 日的研究報告中將 Disc Medicine 的目標價從 90.00 美元上調至 110.00 美元，並給予 “跑贏大盤” 評級。一位投資分析師對該股票給予了強烈買入評級，十位分析師給予買入評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 119.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on IRON</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 IRON 股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine during the 3rd quarter worth approximately $38,000. CWM LLC boosted its holdings in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company's stock worth $55,000 after buying an additional 711 shares in the last quarter. Avanza Fonder AB acquired a new stake in Disc Medicine during the second quarter valued at $57,000. Mirae Asset Global Investments Co. Ltd. grew its position in Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company's stock valued at $71,000 after buying an additional 181 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company's stock valued at $133,000 after buying an additional 206 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了對該公司的持股。Aster Capital Management DIFC Ltd 在第三季度收購了 Disc Medicine 的新股份，價值約 38,000 美元。CWM LLC 在第二季度將其在 Disc Medicine 的持股增加了 213.5%。CWM LLC 目前持有 1,044 股該公司的股票，價值 55,000 美元，此前在上個季度又購買了 711 股。Avanza Fonder AB 在第二季度收購了 Disc Medicine 的新股份，價值 57,000 美元。Mirae Asset Global Investments Co. Ltd.在第二季度將其在 Disc Medicine 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd.目前持有 1,338 股該公司的股票，價值 71,000 美元，此前在此期間又購買了 181 股。最後，Ameritas Investment Partners Inc.在第二季度將其在 Disc Medicine 的持股增加了 8.9%。Ameritas Investment Partners Inc.目前持有 2,515 股該公司的股票，價值 133,000 美元，此前在上個季度又購買了 206 股。當前 83.70% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Disc Medicine</h2>
<div class="lb-trans"><h2>關於 Disc Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.及其子公司是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化針對美國嚴重血液疾病患者的新治療方案。該公司已組建了一系列臨牀和臨牀前產品候選者，旨在改變與紅細胞形成和功能相關的基本生物途徑，主要是血紅素生物合成和鐵穩態。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Disc Medicine</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Disc Medicine</li>
<li>公用事業股票解析 – 如何以及為何投資公用事業</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個明智的買入</li>
<li>投資者如何識別併成功交易缺口下跌股票</li>
<li>RTX 因國防訂單激增而飆升至歷史新高</li>
<li>三大醫療股息股票值得買入和持有</li>
<li>聰明資金正在購買汽車供應商，而不是汽車品牌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=IRON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Disc Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Disc Medicine 嗎？</h2>
</div><p>Before you consider Disc Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Disc Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Disc Medicine 並不在名單上。</p>
</div><p>While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Disc Medicine 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Disc Medicine（納斯達克股票代碼：IRON）的內部人士 William Jacob Savage 出售了 13,093 股股票